{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Complete response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"1"}]}],"title":"Partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"3"}]}],"title":"Stable disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"0"}]}],"title":"Progressive disease (PD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}]}],"title":"Not evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"BOR was defined as the best response recorded from the date of T-cell infusion until disease progression. Response categories from best to worst were, confirmed CR, confirmed PR, stable disease (SD), progressive disease (PD), and not evaluable (NE) (per RECIST v1.1)","groups":[{"description":"Participants who received afamitresgene autoleucel 0.1x10\\^9 transduced cells","id":"OG000","title":"Afamitresgene Autoleucel, Group 1"},{"description":"Participants who received afamitresgene autoleucel 0.5-1.2x10\\^9 transduced cells","id":"OG001","title":"Afamitresgene Autoleucel, Group 2"},{"description":"Participants who received afamitresgene autoleucel 1.2-10x10\\^9 transduced cells","id":"OG002","title":"Afamitresgene Autoleucel, Group 3 + Expansion"},{"description":"Participants who received LDR in combination with lymphodepletion chemotherapy followed by the afamitresgene autoleucel infusion.","id":"OG003","title":"Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who received afamitresgene autoleucel or LDR/ afamitresgene autoleucel","reportingStatus":"POSTED","timeFrame":"From afamitresgene autoleucel infusion until disease progression/recurrence (up to 3.2 years)","title":"Best Overall Response (BOR)","type":"SECONDARY","unitOfMeasure":"Participants"}